The role of NOD-like Receptors in shaping adaptive immunity

Current Opinion in Immunology

Volumn 22, Issue 1, 2010, Pages 34-40

  Williams, Adam ^a,b   Flavell, Richard A ^a,b   Eisenbarth, Stephanie C ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; CRYOPYRIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 33; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; PATTERN RECOGNITION RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; AUTOIMMUNE DISEASE; AUTOINFLAMMATORY DISEASE; B LYMPHOCYTE; CELL DEATH; CELL DIFFERENTIATION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; GENE ACTIVATION; GENE FUNCTION; GENE MUTATION; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; LYMPHOCYTE ACTIVATION; NONHUMAN; PHENOTYPE; REGULATORY MECHANISM; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE; TUMOR IMMUNITY;

ADAPTIVE IMMUNITY; ANIMALS; AUTOIMMUNE DISEASES; HUMANS; IMMUNITY, INNATE; INFLAMMATION; RECEPTORS, PATTERN RECOGNITION;

EID: 77249171672     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coi.2010.01.004     Document Type: Review

References (54)

1. Kumar H., Kawai T., and Akira S. Toll-like receptors and innate immunity. Biochem Biophys Res Commun 388 (2009) 621-625
2. Pichlmair A., and Reis e Sousa C. Innate recognition of viruses. Immunity 27 (2007) 370-383
3. Martinon F., Mayor A., and Tschopp J. The inflammasomes: guardians of the body. Annu Rev Immunol 27 (2009) 229-265
4. Fernandes-Alnemri T., Wu J., Yu J.W., Datta P., Miller B., Jankowski W., Rosenberg S., Zhang J., and Alnemri E.S. The pyroptosome: a supramolecular assembly of ASC dimers mediating inflammatory cell death via caspase-1 activation. Cell Death Differ 14 (2007) 1590-1604
5. Fink S.L., and Cookson B.T. Caspase-1-dependent pore formation during pyroptosis leads to osmotic lysis of infected host macrophages. Cell Microbiol 8 (2006) 1812-1825
6. Willingham S.B., Bergstralh D.T., O'Connor W., Morrison A.C., Taxman D.J., Duncan J.A., Barnoy S., Venkatesan M.M., Flavell R.A., Deshmukh M., et al. Microbial pathogen-induced necrotic cell death mediated by the inflammasome components CIAS1/cryopyrin/NLRP3 and ASC. Cell Host Microbe 2 (2007) 147-159
7. Ting J.P., Lovering R.C., Alnemri E.S., Bertin J., Boss J.M., Davis B.K., Flavell R.A., Girardin S.E., Godzik A., Harton J.A., et al. The NLR gene family: a standard nomenclature. Immunity 28 (2008) 285-287
8. Martinon F., Burns K., and Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 10 (2002) 417-426
9. Arend W.P., Palmer G., and Gabay C. IL-1, IL-18, and IL-33 families of cytokines. Immunol Rev 223 (2008) 20-38
10. Cayrol C., and Girard J.P. The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proc Natl Acad Sci USA 106 (2009) 9021-9026. This study argues that pro-IL-33 is active and that cleavage by casapse-1 results in loss of function.
11. Luthi A.U., Cullen S.P., McNeela E.A., Duriez P.J., Afonina I.S., Sheridan C., Brumatti G., Taylor R.C., Kersse K., Vandenabeele P., et al. Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. Immunity 31 (2009) 84-98. This study also argues that pro-IL-33 is active, but that cleavage by non-caspase-1 caspases results in loss of function.
12. Keller M., Ruegg A., Werner S., and Beer H.D. Active caspase-1 is a regulator of unconventional protein secretion. Cell 132 (2008) 818-831. Using mass spectrometry-based iTRAQ, this study identifies numerous secreted but leaderless products from keratinocytes that require casapse-1.
13. Lamkanfi M., Kanneganti T.D., Van Damme P., Vanden Berghe T., Vanoverberghe I., Vandekerckhove J., Vandenabeele P., Gevaert K., and Nunez G. Targeted peptidecentric proteomics reveals caspase-7 as a substrate of the caspase-1 inflammasomes. Mol Cell Proteomics 7 (2008) 2350-2363. Using LC-MS/MS, this proteomics screen identified cleavage products of caspase-1 in macrophage cell lysates, with a particular focus on caspase-7.
14. Amer A., Franchi L., Kanneganti T.D., Body-Malapel M., Ozoren N., Brady G., Meshinchi S., Jagirdar R., Gewirtz A., Akira S., et al. Regulation of Legionella phagosome maturation and infection through flagellin and host Ipaf. J Biol Chem 281 (2006) 35217-35223
15. Boyden E.D., and Dietrich W.F. Nalp1b controls mouse macrophage susceptibility to anthrax lethal toxin. Nat Genet 38 (2006) 240-244
16. Franchi L., Stoolman J., Kanneganti T.D., Verma A., Ramphal R., and Nunez G. Critical role for Ipaf in Pseudomonas aeruginosa-induced caspase-1 activation. Eur J Immunol 37 (2007) 3030-3039
17. Miao E.A., Alpuche-Aranda C.M., Dors M., Clark A.E., Bader M.W., Miller S.I., and Aderem A. Cytoplasmic flagellin activates caspase-1 and secretion of interleukin 1beta via Ipaf. Nat Immunol 7 (2006) 569-575
18. Nour A.M., Yeung Y.G., Santambrogio L., Boyden E.D., Stanley E.R., and Brojatsch J. Anthrax lethal toxin triggers the formation of a membrane-associated inflammasome complex in murine macrophages. Infect Immun 77 (2009) 1262-1271
19. Kanneganti T.D., Ozoren N., Body-Malapel M., Amer A., Park J.H., Franchi L., Whitfield J., Barchet W., Colonna M., Vandenabeele P., et al. Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3. Nature 440 (2006) 233-236
20. Mariathasan S., Weiss D.S., Newton K., McBride J., O'Rourke K., Roose-Girma M., Lee W.P., Weinrauch Y., Monack D.M., and Dixit V.M. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 440 (2006) 228-232
21. Martinon F., Petrilli V., Mayor A., Tardivel A., and Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440 (2006) 237-241
22. Sutterwala F.S., Ogura Y., Szczepanik M., Lara-Tejero M., Lichtenberger G.S., Grant E.P., Bertin J., Coyle A.J., Galan J.E., Askenase P.W., et al. Critical role for NALP3/CIAS1/Cryopyrin in innate and adaptive immunity through its regulation of caspase-1. Immunity 24 (2006) 317-327
23. Dostert C., Petrilli V., Van Bruggen R., Steele C., Mossman B.T., and Tschopp J. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 320 (2008) 674-677
24. Hornung V., Bauernfeind F., Halle A., Samstad E.O., Kono H., Rock K.L., Fitzgerald K.A., and Latz E. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol 9 (2008) 847-856. One of seven papers describing the activation of the NLRP3 inflammasome by alum. While this study did not evaluate the in vivo effect of NLRP3-deficiency upon alum immunization, it did look at one potential mechanism of NLRP3 activation resulting from lysosomal disruption following alum phagocytosis.
25. Petrilli V., Papin S., Dostert C., Mayor A., Martinon F., and Tschopp J. Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration. Cell Death Differ 14 (2007) 1583-1589
26. Bauernfeind F.G., Horvath G., Stutz A., Alnemri E.S., MacDonald K., Speert D., Fernandes-Alnemri T., Wu J., Monks B.G., Fitzgerald K.A., et al. Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J Immunol 183 (2009) 787-791. An important study clarifying the role of 'signal 1' in licensing of the inflammasome by multiple NF-κB activators.
27. Franchi L., Eigenbrod T., and Nunez G. Cutting edge: TNF-alpha mediates sensitization to ATP and silica via the NLRP3 inflammasome in the absence of microbial stimulation. J Immunol 183 (2009) 792-796. This paper also maintains that 'signal 1' can come from numerous stimuli including cytokines and IL-1beta.
28. Kobayashi K.S., Chamaillard M., Ogura Y., Henegariu O., Inohara N., Nunez G., and Flavell R.A. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 307 (2005) 731-734
29. Fritz J.H., Le Bourhis L., Sellge G., Magalhaes J.G., Fsihi H., Kufer T.A., Collins C., Viala J., Ferrero R.L., Girardin S.E., et al. Nod1-mediated innate immune recognition of peptidoglycan contributes to the onset of adaptive immunity. Immunity 26 (2007) 445-459
30. Watanabe H., Gehrke S., Contassot E., Roques S., Tschopp J., Friedmann P.S., French L.E., and Gaide O. Danger signaling through the inflammasome acts as a master switch between tolerance and sensitization. J Immunol 180 (2008) 5826-5832
31. Babelova A., Moreth K., Tsalastra-Greul W., Zeng-Brouwers J., Eickelberg O., Young M.F., Bruckner P., Pfeilschifter J., Schaefer R.M., Grone H.J., et al. Biglycan, a danger signal that activates the NLRP3 inflammasome via toll-like and P2X receptors. J Biol Chem 284 (2009) 24035-24048
32. Iyer S., Pulskensc W., Sadler J., Butter L., Teske G., Ulland T., Eisenbarth S., Florquin S., Flavell R., Leemans J., et al. Necrotic cells trigger a sterile inflammatory response through the Nlrp3 inflammasome. PNAS 106 (2009) 20388-20393
33. Li H., Ambade A., and Re F. Cutting edge: necrosis activates the NLRP3 inflammasome. J Immunol 183 (2009) 1528-1532
34. Yamasaki K., Muto J., Taylor K.R., Cogen A.L., Audish D., Bertin J., Grant E.P., Coyle A.J., Misaghi A., Hoffman H.M., et al. NLRP3/cryopyrin is necessary for interleukin-1beta (IL-1beta) release in response to hyaluronan, an endogenous trigger of inflammation in response to injury. J Biol Chem 284 (2009) 12762-12771
35. Ghiringhelli F., Apetoh L., Tesniere A., Aymeric L., Ma Y., Ortiz C., Vermaelen K., Panaretakis T., Mignot G., Ullrich E., et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 15 (2009) 1170-1178. A thorough study of the adjuvant effect of chemotherapeutic-treated tumor cells. This paper argues that ATP released by dying cells, acting through P2x7R and HMGB1, activates the NLRP3 inflammasome thereby initiating adaptive anti-tumor immunity.
36. Shi Y., Evans J.E., and Rock K.L. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 425 (2003) 516-521
37. Eisenbarth S.C., Colegio O.R., O'Connor W., Sutterwala F.S., and Flavell R.A. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 453 (2008) 1122-1126. One of seven papers describing the activation of the NLRP3 inflammasome by alum. Our study found a reduced T and B cell response in vivo in an OVA/alum asthma model.
38. Franchi L., and Nunez G. The Nlrp3 inflammasome is critical for aluminium hydroxide-mediated IL-1beta secretion but dispensable for adjuvant activity. Eur J Immunol 38 (2008) 2085-2089. One of seven papers describing the activation of the NLRP3 inflammasome by alum. This study failed to see a difference in antibody responses to antigens injected with alum in vivo in NLRP3-deficient mice.
39. Kool M., Petrilli V., De Smedt T., Rolaz A., Hammad H., van Nimwegen M., Bergen I.M., Castillo R., Lambrecht B.N., and Tschopp J. Cutting edge: alum adjuvant stimulates inflammatory dendritic cells through activation of the NALP3 inflammasome. J Immunol 181 (2008) 3755-3759. One of seven papers describing the activation of the NLRP3 inflammasome by alum. This study found reduced DC activation in NLRP3-deficient mice immunized with antigen in alum and did find reduced antigen-specific IgE but also found increased IgG2c.
40. Li H., Willingham S.B., Ting J.P., and Re F. Cutting edge: inflammasome activation by alum and alum's adjuvant effect are mediated by NLRP3. J Immunol 181 (2008) 17-21. One of seven papers describing the activation of the NLRP3 inflammasome by alum. Using a tetanus toxoid-alum in vivo model, this group found reduced antigen-specific antibody production in NLRP3-deficient mice and also found that the adjuvants Quil A and chitosan also activate the NLRP3 inflammasome.
41. McKee A.S., Munks M.W., MacLeod M.K., Fleenor C.J., Van Rooijen N., Kappler J.W., and Marrack P. Alum induces innate immune responses through macrophage and mast cell sensors, but these sensors are not required for alum to act as an adjuvant for specific immunity. J Immunol 183 (2009) 4403-4414. One of seven papers describing the activation of the NLRP3 inflammasome by alum. However, this group found no role for the NLRP3 inflammasome in the adaptive immune response in vivo to antigen in alum.
42. Sharp F.A., Ruane D., Claass B., Creagh E., Harris J., Malyala P., Singh M., O'Hagan D.T., Petrilli V., Tschopp J., et al. Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome. Proc Natl Acad Sci USA 106 (2009) 870-875. One of seven papers describing the activation of the NLRP3 inflammasome by alum. While this paper mostly focused on the actions of microparticles in vivo, the authors did find in vitro NLRP3 activation by alum particles.
43. Kool M., Soullie T., van Nimwegen M., Willart M.A., Muskens F., Jung S., Hoogsteden H.C., Hammad H., and Lambrecht B.N. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J Exp Med 205 (2008) 869-882. A thorough study of DC activation following alum immunization in mice. This paper concludes that uric acid and the MyD88 pathway are crucial to the immunogenicity of alum and that the mediastinal LN rather than the spleen is the site of adaptive activation following i.p. immunization.
44. Marrack P., McKee A.S., and Munks M.W. Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol 9 (2009) 287-293
45. Demento S.L., Eisenbarth S.C., Foellmer H.G., Platt C., Caplan M.J., Mark Saltzman W., Mellman I., Ledizet M., Fikrig E., Flavell R.A., et al. Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy. Vaccine 27 (2009) 3013-3021
46. Kolly L., Karababa M., Joosten L.A., Narayan S., Salvi R., Petrilli V., Tschopp J., van den Berg W.B., So A.K., and Busso N. Inflammatory role of ASC in antigen-induced arthritis is independent of caspase-1, NALP-3, and IPAF. J Immunol 183 (2009) 4003-4012
47. Allen I.C., Scull M.A., Moore C.B., Holl E.K., McElvania-TeKippe E., Taxman D.J., Guthrie E.H., Pickles R.J., and Ting J.P. The NLRP3 inflammasome mediates in vivo innate immunity to influenza A virus through recognition of viral RNA. Immunity 30 (2009) 556-565
48. Ichinohe T., Lee H.K., Ogura Y., Flavell R., and Iwasaki A. Inflammasome recognition of influenza virus is essential for adaptive immune responses. J Exp Med 206 (2009) 79-87
49. Thomas P.G., Dash P., Aldridge Jr. J.R., Ellebedy A.H., Reynolds C., Funk A.J., Martin W.J., Lamkanfi M., Webby R.J., Boyd K.L., et al. The intracellular sensor NLRP3 mediates key innate and healing responses to influenza A virus via the regulation of caspase-1. Immunity 30 (2009) 566-575
50. Jin Y., Mailloux C.M., Gowan K., Riccardi S.L., LaBerge G., Bennett D.C., Fain P.R., and Spritz R.A. NALP1 in vitiligo-associated multiple autoimmune disease. N Engl J Med 356 (2007) 1216-1225
51. Hitomi Y., Ebisawa M., Tomikawa M., Imai T., Komata T., Hirota T., Harada M., Sakashita M., Suzuki Y., Shimojo N., et al. Associations of functional NLRP3 polymorphisms with susceptibility to food-induced anaphylaxis and aspirin-induced asthma. J Allergy Clin Immunol 124 (2009) 779-785 e776
52. Brydges S.D., Mueller J.L., McGeough M.D., Pena C.A., Misaghi A., Gandhi C., Putnam C.D., Boyle D.L., Firestein G.S., Horner A.A., et al. Inflammasome-mediated disease animal models reveal roles for innate but not adaptive immunity. Immunity 30 (2009) 875-887. An elegant paper describing the characterization of a constitutively activate NLRP3 mutation to mimic a mouse model of CAPS. This study found no significant role for the adaptive immune system in the autoinflammatory disease process.
53. Meng G., Zhang F., Fuss I., Kitani A., and Strober W. A mutation in the Nlrp3 gene causing inflammasome hyperactivation potentiates Th17 cell-dominant immune responses. Immunity 30 (2009) 860-874. An intriguing study also describing the characterization of a constitutively activate NLRP3 mutation to mimic a mouse model of CAPS. This study found increased Th17 cell populations, increased activation state of T cells and autoantibodies in the autoinflammatory model.
54. Ivanov I.I., Atarashi K., Manel N., Brodie E.L., Shima T., Karaoz U., Wei D., Goldfarb K.C., Santee C.A., Lynch S.V., et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell (2009)